Trexquant Investment’s Fulcrum Therapeutics FULC Stock Holding History

Trexquant Investment’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.48M	Buy	453,529 +97,982	+28%	+$909K	0.03%	795
2025 Q4	$4.02M	Buy	355,547 +334,532	+1,592%	+$3.4M	0.04%	689
2025 Q3	$193K	Buy	+21,015	New	+$152K	﹤0.01%	1507
2024 Q3	–	Sell	-70,506	Closed	-$437K	–	1641
2024 Q2	$437K	Buy	70,506 +23,284	+49%	+$176K	0.01%	1288
2024 Q1	$446K	Buy	+47,222	New	+$422K	0.01%	1183
2022 Q4	–	Sell	-13,886	Closed	-$112K	–	1490
2022 Q3	$112K	Buy	+13,886	New	+$99.4K	﹤0.01%	1278

Other funds holding FULC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

FTM

First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Trexquant Investment's FULC Position: Q1 2026 in Review

Trexquant Investment increased its Fulcrum Therapeutics (FULC) stake by 28% in Q1 2026, buying an estimated $909K and bringing the position to 453,529 shares worth $3.48M. The position accounts for 0.03% of the portfolio, ranked #795.

Trexquant Investment first reported a position in FULC in Q3 2022 and has held it in 6 quarters since. The position peaked at $4.02M in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

Trexquant Investment held 453,529 shares of Fulcrum Therapeutics worth $3.48M as of Q1 2026.
Trexquant Investment bought 97,982 Fulcrum Therapeutics shares in Q1 2026, an estimated $909K.
Fulcrum Therapeutics made up 0.03% of Trexquant Investment's portfolio in Q1 2026, its #795 holding.
Trexquant Investment first reported a position in Fulcrum Therapeutics in Q3 2022 and has held it in 6 quarters since.
Trexquant Investment's Fulcrum Therapeutics position peaked at $4.02M in Q4 2025.
169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Trexquant Investment's 13F filing for Q1 2026, filed 15 May 2026.